期刊文献+

人白介素-8 shRNA慢病毒载体的构建和鉴定

Construction and identification of shRNA lentiviral vector targeting human interleukin-8 gene
下载PDF
导出
摘要 目的:构建携载人白介素-8(IL-8)shRNA的慢病毒并鉴定其对MDA-MB-231细胞该基因的沉默效率。方法:设计两个IL-8基因特异性siRNA靶点,与pMagic7.1慢病毒载体质粒重组,经PCR鉴定并测序,通过293T细胞实现慢病毒包装,DNA定量试剂盒分别检测两种慢病毒滴度。将这两种慢病毒分别以最佳感染复数感染MDA-MB-231细胞,通过Real-time PCR检测IL-8沉默效率。结果:PCR鉴定阳性的shRNA重组质粒测序正确,包装后两种病毒滴度分别为1.93×109 IU/mL和1.89×109IU/mL;分别以MOI=40感染MDA-MB-231细胞后,IL-8沉默效率分别为80%和90%。结论:成功构建IL-8 shRNA慢病毒并达到较高的沉默效率,为下一步研究沉默靶基因后细胞生物学功能变化提供实验基础。 Objective: This study aims to target human interleukin-8 gene by constructing shRNA lentiviral vectors and detect its silencing effect in MDA-MB-231 cells. Methods: Two specific siRNA sequences targeting human IL-8 gene were designed and recombined with pMagic7.1 lentiviral vector plasmids. The recombined plasmids were identified by PCR and then sequenced. The lentivirus particles were packaged using 293T cells,the titer of which were detected by quantitative DNA technique. Then MDA-MB-231 cells were transfected with the optimized MOI. The silencing effect on IL-8 was detected by real-time PCR. Results: The sequencing of shRNA plasmids which been identified positive by PCR were correctly constructed. The titer of the packaged virus was 1.93 × 10^9 IU/mL and 1.89 x× 10^9 IU/mL separately. After infecting the MDA-MB-231 ceils with MQI=40, the silencing efficiency were 80% and 90% respectively. Conelusion:The recombinant lentiviral shRNA has been constructed successfully, with a highly silence efficiency, which ensure the reliability for the further study on cell functional assay.
出处 《中国现代普通外科进展》 CAS 2014年第4期263-265,289,共4页 Chinese Journal of Current Advances in General Surgery
基金 南京军区科研计划课题(10MA081)
关键词 白介素-8 RNA干扰 慢病毒 乳腺肿瘤 基因沉默 Interleukin-8 RNA interference Lentiviral Breast neoplasmso Gene silencing
  • 相关文献

参考文献2

二级参考文献20

  • 1徐佳,刘志锋,姜勇.高迁移率族蛋白与真核基因表达调控[J].生物化学与生物物理进展,2005,32(5):397-402. 被引量:19
  • 2赵菲,姜军,范林军,杨新华,张毅.P糖蛋白在乳腺癌原发性耐药过程中的表达[J].第四军医大学学报,2005,26(16):1513-1516. 被引量:2
  • 3Sun J, He ZG, Cheng G, et al. Muhidrug resistance P-glycoprotein. Crucial significance in drug disposition and interaction[J]. Med Sci Monit,2004, 10(1):5.
  • 4Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, et al. P-glycoprotein. From genomics to mechanism [ J ]. Oncogene, 2003,22 (47) : 7468.
  • 5Lacave R,Goulet F,Ricci S,et al. Comparative evaluation by semiquantitative reverse transcriptase polymerase chain reaction of MDR1. MRP and GSTp gene expression in breast carcinomas[J]. Br J Cancer, 1998,77(5):694.
  • 6Kanzaki A, Yoi M, Nakayama K, et al. Expression of multidrug resistancerelated transporters in human breast carcinoma [ J] .Jpn J Cancer Res, 2001,92(4) :452.
  • 7Kage K,Tsukahara S, Sugiyama T, et al. Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization[J]. Int J Cancer,2002,97:626.
  • 8Pohl G, FiliPits M,Suchomel RW, et al. Expression of the lung resistance protein (LRP) in primary breast cancer [ J ]. Anticancer Res, 1999, 19 (6B) :5051.
  • 9Fire A. XuSQ, Monlgemery M K, Potent and specific genetic interference by double-stranded RNA in caenor habditis elegans[J]. Nature, 1998,391 (6669) :806.
  • 10Abbas-Terki T,Blanco-Bose W,Deglon N,et al.Lentiviral mediated RNA interference[J].Hum Gene Ther,2002,13(18):2197.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部